Methionine γ-lyase (MGL) catalyzes the degradation of methionine. This activity is exploited as antitumor agent, because methionine depletion blocks tumor cell cycle and leads to an increased susceptibility to other anticancer drugs. The aim of PR.A.M. project is to conjugate gold nanoparticels with the enzyme in order to deliver it to cancer cells and to increase the bioavailability. The cytotoxicity of the conjugates will be evaluated on a panel of cancer cells and a complete characterization of the conjugate will be performed.
Call for proposal: Nanobiotechnology laboratory
Lead institution
Istituto di Biofisica – Sez. Di Pisa (Consiglio Nazionale delle Ricerche)
Institution
- Università di Parma (Dipartimento di Scienze degli Alimenti e del Farmaco, and Istituto di Biofisica) (IT)
- Reference
- PR.A.M.
- Project locations
- Italy